4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly Income from Continuing Operations came in at 94911000.0 in Q1 2026, down 91.98% year-on-year from 1182834617.85 in Q1 2025, and down 626.73% on a QoQ basis from 18019000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Income from Continuing Operations data on file, last reported at 94911000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 91.98% year-over-year to 94911000.0 in Q1 2026; TTM through Mar 2026 was 252655000.0, a 13.1% decrease from a year earlier, with the FY2025 full-year figure at 298627000.0, down 3.38% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 94911000.0, down from 18019000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for FDMT reached as high as 18019000.0 in Q4 2025 and fell as low as 94911000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 48399470.59 across 5 years, with a median of 47319000.0 in 2022.
- Across the five-year window, Income from Continuing Operations slumped 217.09% in 2022 and surged 135.65% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 30282000.0 in 2022, then fell by 9.21% to 33072000.0 in 2023, then tumbled by 52.85% to 50550000.0 in 2024, then jumped by 135.65% to 18019000.0 in 2025, then plunged by 626.73% to 94911000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 94911000.0 in Q1 2026, 18019000.0 in Q4 2025, and 85876000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | -94.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.91 Mn |
| Dec 31, 2025 | 18.02 Mn |
| Sep 30, 2025 | -85.88 Mn |
| Jun 30, 2025 | -89.89 Mn |
| Mar 31, 2025 | -49.44 Mn |
| Dec 31, 2024 | -50.55 Mn |
| Sep 30, 2024 | -77.95 Mn |
| Jun 30, 2024 | -45.45 Mn |
| Mar 31, 2024 | -39.06 Mn |
| Dec 31, 2023 | -33.07 Mn |
| Sep 30, 2023 | -29.08 Mn |
| Jun 30, 2023 | -51.28 Mn |
| Mar 31, 2023 | -49.29 Mn |
| Dec 31, 2022 | -30.28 Mn |
| Sep 30, 2022 | -47.32 Mn |
| Jun 30, 2022 | -34.23 Mn |
| Mar 31, 2022 | -33.13 Mn |
| Dec 31, 2021 | -26.28 Mn |
| Sep 30, 2021 | -47.53 Mn |
| Jun 30, 2021 | -10.79 Mn |